Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2022 17:00 ET | Source: Imunon, Inc.

Imunon Appoints James E. Dentzer to its Board of Directors

CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug...
October 03, 2022 08:00 ET | Source: Imunon, Inc.

Imunon Reports Partial Results from Ongoing Non-human Primate Study

Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
September 29, 2022 17:00 ET | Source: Imunon, Inc.

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
September 27, 2022 08:30 ET | Source: Imunon, Inc.

IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference

LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief...
September 19, 2022 16:30 ET | Source: Celsion Corporation

Celsion Corporation Announces Company Name Change to Imunon, Inc.

New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion...
September 15, 2022 08:30 ET | Source: Celsion Corporation

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE)...
September 12, 2022 18:30 ET | Source: Celsion Corporation

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief...
September 07, 2022 09:15 ET | Source: Celsion Corporation

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief...
September 01, 2022 08:30 ET | Source: Celsion Corporation

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company...
August 15, 2022 08:00 ET | Source: Celsion Corporation

Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. ...